Here, we evaluated the <i>in vitro</i> therapeutic potential of PS-L in macrophages from people with cystic fibrosis (pwCF), either under therapeutic regimen or not with CFTR modulator therapy Elexacaftor/Tezacaftor/Ivacaftor (ETI). The gene discussed is CFTR; the disease is cystic fibrosis.